Abstract
It had previously been supposed that antiplatelet therapy did not influence venous thromboembolism, and many surgeons and physicians do not use it routinely for thromboprophylaxis, even for patients who are at substantial risk of deep venous thrombosis or pulmonary embolism. These results indicate that antiplatelet therapy--either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis (such as subcutaneous heparin)--should be considered.
Keywords
MedicinePulmonary embolismVenous thrombosisThrombosisSurgeryRandomized controlled trialAntiplatelet drugVenographyRegimenInternal medicineAspirinClopidogrel
Related Publications
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patient...
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were ...
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. We studied consecutive symptomatic patients with l...
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. ...
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Oral antiplatelet drugs are a cornerstone of modern pharmacotherapy in cardiovascular atherothrombotic diseases. The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidog...
Publication Info
- Year
- 1994
- Type
- article
- Volume
- 308
- Issue
- 6923
- Pages
- 235-46
- Citations
- 564
- Access
- Closed
External Links
Citation Metrics
564
OpenAlex
Cite This
(1994).
Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration..
PubMed
, 308
(6923)
, 235-46.